USPTO serial 85963028
SMARTAG
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 4, 2016
- Examiner
- LEVINE, HOWARD B
- Law office
- TMO LAW OFFICE 115
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with SMARTAG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
CATALENT PHARMA SOLUTIONS, INC.
Somerset, NJ
CATALENT PHARMA SOLUTIONS, INC.
Somerset, NJ
CATALENT PHARMA SOLUTIONS, INC.
Somerset, NJ
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Vanessa A. Ignacio,
Vanessa A. Ignacio, LOWENSTEIN SANDLER LLPOne Lowenstein DriveROSELAND, NJ 07068UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical and biological reagents in the nature of or used to create or improve antibody-drug conjugates or any protein conjugated to a drug, poly nucleotide, another protein, chemical, or other functional entity used in industry and science; chemicals for use in bioconjugation, reversible bioconjugation, irreversible bioconjugation, reversible cysteine protection, surface modification, and prodrug production for scientific use; biochemicals, namely, polypeptides, polypeptides for in vivo applications, polypeptides for in vitro applications, polynucleic acids, polynucleic acids for in vivo applications, and polynucleic acids for in vitro applications for scientific use; biomolecules, namely, proteins, peptides, antibodies, antibody fragments, antibody mimetic proteins, and polynucleic acids for scientific use; chemical products for diagnostic use, namely, conjugates of polypeptides with small molecule drugs, imaging agents, flourocromes and radiolabels for medical research applications; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in basic scientific research and development, medical research; diagnostic preparations for scientific or research use in connection with antibody drug conjugates; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system | ACTIVE | Oct 20, 2014 |
| 005 | Pharmaceutical preparations for the prevention or treatment of human diseases, namely, diseases of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; chemical, biological and biochemical preparations for medical and pharmaceutical purposes, namely, antibody-drug conjugates or any protein conjugated to a drug, poly nucleotide, another protein, chemical, or other functional entity or such preparations used as linker or payload molecules therein used to treat cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; pharmaceutical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; biological preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; diagnostic preparations for medical purposes in connection with the diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; antibody preparations, namely, antibody or protein bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system, including antibody/protein-drug conjugates, antibody/protein-radiolabled conjugates and antibody/protein-imaging agent conjugates; chemical products for medical diagnostic use, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; biochemical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system | ACTIVE | Oct 20, 2014 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CATALENT PHARMA SOLUTIONS, INC.
- Other trademarks owned by CATALENT PHARMA SOLUTIONS, INC.
- Other trademarks owned by CATALENT PHARMA SOLUTIONS, INC.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named SMARTAG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 4, 2025 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Dec 25, 2024 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Oct 5, 2023 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Oct 5, 2023 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Oct 5, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 4, 2023 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Oct 4, 2021 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 22, 2019 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Oct 4, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 31, 2016 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Aug 30, 2016 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Aug 9, 2016 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Aug 6, 2016 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 13, 2016 | IUAF | USE AMENDMENT FILED | — |
| Jul 13, 2016 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 19, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 15, 2016 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 15, 2016 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 15, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 2, 2015 | PCGR | PETITION TO DIRECTOR GRANTED | — |
| Aug 31, 2015 | APET | ASSIGNED TO PETITION STAFF | — |
| Aug 4, 2015 | TPDR | TEAS PETITION TO DIRECTOR RECEIVED | — |
| Jul 28, 2015 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 25, 2015 | CHPN | POST PUBLICATION AMENDMENT – NOT ENTERED | — |
| Jul 22, 2015 | APET | ASSIGNED TO PETITION STAFF | — |
| Jul 16, 2015 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jun 16, 2015 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Dec 23, 2014 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Dec 2, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 2, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 12, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 28, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 28, 2014 | ALIE | ASSIGNED TO LIE | — |
| Oct 9, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 17, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 17, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 17, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 2, 2014 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2014 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 10, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 10, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 16, 2013 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2013 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 10, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 28, 2013 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Jun 27, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 21, 2013 | NWAP | NEW APPLICATION ENTERED | — |